Research company Kancera has received a final grant to one of the company’s cancer projects.
The grant is given by the Swedish innovation authority Vinnova which has identified Kancera as a young innovative company with growth potential. The company develops new treatment methods for cancer and their ROR project has been allocated another SEK 500 000. In total, the project has received SEK 1.5 million in funding from Vinnova.
Within the ROR project Kancera is developing a drug candidate that inhibits a specific family of receptors, ROR-1 and ROR-2.